Impact of Zoledronic Acid and Denosumab Treatment on Growth Factor Concentration in Platelet Rich Fibrin of Patients With Osteolytic Bone Metastases.
Adult
Aged
Aged, 80 and over
Bone Density Conservation Agents
/ pharmacology
Bone Neoplasms
/ blood
Breast Neoplasms
/ blood
Denosumab
/ pharmacology
Female
Humans
Intercellular Signaling Peptides and Proteins
/ blood
Leukocyte Count
Male
Middle Aged
Osteolysis
/ blood
Platelet Count
Platelet-Rich Fibrin
/ drug effects
Prostatic Neoplasms
/ blood
Young Adult
Zoledronic Acid
/ pharmacology
Platelet rich fibrin
bisphosphonates
denosumab
growth factor
zoledronic acid
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
28
04
2021
revised:
02
07
2021
accepted:
05
07
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
29
7
2021
Statut:
ppublish
Résumé
Side effects of zolendronic acid (ZA) and RANKL inhibitors (RANKL-I) include impaired wound healing and osteonecrosis of the jaw. Platelet rich fibrin (PRF) enhances wound healing and bone remodelling in vivo and in vitro. However, the topical use PRF in the surgical treatment of patients with medicament-related osteonecrosis of the jaw is relatively new and not thoroughly investigated. Furthermore, the potential attenuation of the PRF effect following antiresorptive treatment remains unclear. Therefore, we investigated the concentration of growth factors within the PRF in healthy volunteers and in patients with antiresorptive treatment. Blood samples from healthy volunteers and patients were used to produce PRF. The levels of EGF, VEGF, PDGF-BB, TGF-β1, BMP-2, and CD31 in the PRF was investigated by ELISA. ZA treatment induced a significant decrease in EGF and TGF-β1 levels, whereas RANKL-I caused lower TGF-β1 levels. Reduced EGF levels in PRF after ZA treatment may explain the delayed wound healing and question the positive effect of PRF in these patients. PRF use in patients undergoing RANKL-I treatment seems to be more justified.
Sections du résumé
BACKGROUND/AIM
Side effects of zolendronic acid (ZA) and RANKL inhibitors (RANKL-I) include impaired wound healing and osteonecrosis of the jaw. Platelet rich fibrin (PRF) enhances wound healing and bone remodelling in vivo and in vitro. However, the topical use PRF in the surgical treatment of patients with medicament-related osteonecrosis of the jaw is relatively new and not thoroughly investigated. Furthermore, the potential attenuation of the PRF effect following antiresorptive treatment remains unclear. Therefore, we investigated the concentration of growth factors within the PRF in healthy volunteers and in patients with antiresorptive treatment.
PATIENTS AND METHODS
Blood samples from healthy volunteers and patients were used to produce PRF. The levels of EGF, VEGF, PDGF-BB, TGF-β1, BMP-2, and CD31 in the PRF was investigated by ELISA.
RESULTS
ZA treatment induced a significant decrease in EGF and TGF-β1 levels, whereas RANKL-I caused lower TGF-β1 levels.
CONCLUSION
Reduced EGF levels in PRF after ZA treatment may explain the delayed wound healing and question the positive effect of PRF in these patients. PRF use in patients undergoing RANKL-I treatment seems to be more justified.
Identifiants
pubmed: 34281854
pii: 41/8/3917
doi: 10.21873/anticanres.15187
doi:
Substances chimiques
Bone Density Conservation Agents
0
Intercellular Signaling Peptides and Proteins
0
Denosumab
4EQZ6YO2HI
Zoledronic Acid
6XC1PAD3KF
Types de publication
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3917-3923Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.